MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, announced that CEO Dr. Jennifer Buell will deliver a plenary address at the 10th Annual CAR-TCR Summit in Boston, MA (September 23-26, 2025).
During her presentation, Dr. Buell will share first-in-human data from MiNK's iNKT platform, demonstrating durable disease reversal and steroid-free remission in severe immune collapse. The company's off-the-shelf approach is designed to be administered without HLA matching or lymphodepletion, focusing on treating autoimmunity and pulmonary failure.
MiNK Therapeutics (Nasdaq: INKT), una società biofarmaceutica in fase clinica specializzata in terapie a cellule iNKT, ha annunciato che la CEO Dott.ssa Jennifer Buell terrà un intervento plenary al 10th Annual CAR-TCR Summit a Boston, MA (23-26 settembre 2025).
Durante la sua presentazione, la Dott.ssa Buell presenterà dati first-in-human dalla piattaforma iNKT di MiNK, dimostrando una reversibilità duratura della malattia e una remissione senza corticosteroidi in casi di grave collasso immunitario. L'approccio off-the-shelf dell'azienda è progettato per essere somministrato senza corrispondenza HLA o chemioterapia di linfodeplezione, con l'obiettivo di trattare autoimmunità e insufficienza polmonare.
MiNK Therapeutics (Nasdaq: INKT), una empresa biofarmacéutica en etapa clínica especializada en terapias con células iNKT, anunció que la directora ejecutiva, la Dra. Jennifer Buell, ofrecerá una conferencia plenaria en la 10th Annual CAR-TCR Summit en Boston, MA (del 23 al 26 de septiembre de 2025).
Durante su presentación, la Dra. Buell compartirá datos first-in-human de la plataforma iNKT de MiNK, que demuestran una reversión duradera de la enfermedad y remisión sin esteroides en casos de colapso inmunológico severo. El enfoque listos-para-usar de la empresa está diseñado para administrarse sin compatibilidad HLA ni linfodepleción, y se centra en tratar la autoinmunidad y la insuficiencia pulmonar.
MiNK Therapeutics (Nasdaq: INKT)는 iNKT 세포 치료제를 전문으로 하는 임상 1상 중인 생명공학 회사로, CEO Jennifer Buell 박사가 보스턴, MA에서 열리는 10th Annual CAR-TCR Summit에서 기조 발표를 할 예정이라고 발표했습니다(2025년 9월 23–26일).
발표 중 Buell 박사는 MiNK의 iNKT 플랫폼에서 in-human data를 공유하여 중증 면역 붕괴에서 질병의 지속 가능한 역전과 코르티코스테로이드 없이의 관해를 증명할 예정입니다. 회사의 오프-더-셀프 접근 방식은 HLA 매칭이나 림포사이트 소실 전처리 없이 투여되도록 설계되었으며, 자가면역과 폐부전 치료에 중점을 둡니다.
MiNK Therapeutics (Nasdaq: INKT), une société biopharmaceutique en phase clinique spécialisée dans les thérapies par cellules iNKT, a annoncé que la PDG Dr. Jennifer Buell prononcera une allocution plénière au 10th Annual CAR-TCR Summit à Boston, MA (du 23 au 26 septembre 2025).
Lors de sa présentation, la Dr Buell partagera des données first-in-human de la plateforme iNKT de MiNK, démontrant une réversion durable de la maladie et une rémission sans corticostéroïdes dans les cas de défaillance immunitaire sévère. L’approche prête-à-l’emploi de l’entreprise est conçue pour être administrée sans correspondance HLA ni lymphodepletion, et vise le traitement de l’auto-immunité et de l’insuffisance pulmonaire.
MiNK Therapeutics (Nasdaq: INKT), ein klinisch phasenorientiertes Biopharma-Unternehmen, das sich auf iNKT-Zelltherapien spezialisiert hat, gab bekannt, dass CEO Dr. Jennifer Buell eine Plenarrede auf dem 10th Annual CAR-TCR Summit in Boston, MA (23.–26. September 2025) halten wird.
In ihrem Vortrag wird Dr. Buell First-in-Human-Daten aus MiNKs iNKT-Plattform vorstellen, die eine anhaltende Krankheitsumkehr und remission ohne Steroide bei schwerer immunologischer Desintegration zeigen. Der Off-the-Shelf-Ansatz des Unternehmens soll ohne HLA-Anpassung oder Lymphodepletion verabreicht werden und konzentriert sich auf die Behandlung von Autoimmunität und pulmonaler Versagen.
MiNK Therapeutics (Nasdaq: INKT)، شركة أدوية حيوية في مرحلة إكلينيكية تتخصص في علاجات خلايا iNKT، أعلنت أن المديرة التنفيذية الدكتورة Jennifer Buell ستلقي كلمة رئيسة في 10th Annual CAR-TCR Summit في بوسطن، ماساتشوستس (من 23 إلى 26 سبتمبر 2025).
خلال عرضها، ستشارك الدكتورة Buell بيانات first-in-human من منصة MiNK لـ iNKT، والتي تُظهر عكس المرض بشكل دائم وارتكاز remission بدون ستيرويدات في حالات انهيار مناعي حاد. نهج الشركة الجاهز للاستخدام يهدف إلى أن يُعطى دون تطابق HLA أو استئصال لمفاوي، مع التركيز على علاج المناعة الذاتية وفشل الرئة.
MiNK Therapeutics (纳斯达克股票代码：INKT)，一家专注于不变天然杀伤细胞（iNKT）治疗的临床阶段生物制药公司，宣布首席执行官 Jennifer Buell 博士将于在波士顿、马萨诸塞州举行的第10届CAR-TCR峰会上发表全体演讲，时间为2025年9月23-26日。
在演讲中，Buell 博士将分享来自MiNK iNKT 平台的< b>手术前人体数据，显示在严重免疫崩溃情形下疾病可持续逆转并实现不依赖类固醇的缓解。该公司现成药物（off-the-shelf）方案设计为无需HL A匹配或淋巴清除即可给药，聚焦治疗自身免疫和肺部衰竭。
- None.
- None.
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced that its President and Chief Executive Officer, Dr. Jennifer Buell, will deliver a featured plenary address at the 10th Annual CAR-TCR Summit, taking place September 23–26, 2025, in Boston, MA.
The CAR-TCR Summit is one of the industry’s most influential gatherings of academic, clinical, and biopharma leaders advancing the future of cell therapy across oncology, autoimmunity, and immune-mediated disease. Dr. Buell will present during a plenary session titled “Examining the Scope of Cell Therapy Beyond Oncology & Reviewing the Successes & Failures.” In her remarks, Dr. Buell will share first-in-human data from MiNK’s iNKT platform demonstrating durable disease reversal and steroid-free remission in severe immune collapse. She will also outline MiNK’s translational strategy, highlighting how precision trial design, patient stratification, and tissue-specific targeting can accelerate development across high-burden, non-oncology indications.
“The CAR-TCR Summit is the definitive global meeting for engineered cell therapy, and I am honored to contribute to this milestone anniversary,” said Dr. Buell. “MiNK is demonstrating that iNKT cells can restore immune balance in diseases where options are scarce — from autoimmunity to pulmonary failure. Our off-the-shelf approach is designed to be scalable, broadly accessible, and uniquely administered without the need for HLA matching or lymphodepletion, opening the door to truly transformative patient care.”
About the 10th CAR-TCR Summit
Celebrating a decade of innovation, the CAR-TCR Summit is the preeminent global forum for the cell therapy community, bringing together over 800 stakeholders—including C-suite executives, leading scientists, investors, and regulators from across the end-to-end value chain. With 100+ world-class speakers and six simultaneous content tracks spanning discovery to commercialization, the 2025 Summit showcases the latest breakthroughs in CAR-T, TCR, and iNKT cell therapies across oncology, autoimmune disease, and beyond. MiNK Therapeutics joins a roster of innovators and market leaders advancing the frontiers of cellular medicine.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead asset, agenT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit https://minktherapeutics.com or follow us on X @MiNK_iNKT.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, anticipated benefit, development plans, and future potential of iNKT cells and CAR-iNKT therapies. These forward-looking statements are subject to risks and uncertainties, including those described under the “Risk Factors” section of MiNK’s most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
Contacts
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
FAQ
When is Dr. Jennifer Buell presenting at the CAR-TCR Summit 2025?
What clinical data will MiNK Therapeutics (INKT) present at the CAR-TCR Summit?
What are the advantages of MiNK Therapeutics' (INKT) cell therapy approach?
What therapeutic areas is MiNK Therapeutics (INKT) targeting with their iNKT cell therapy?
